How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Siponimod for treating secondary progressive multiple sclerosis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about siponimod

Marketing authorisation indication

2.1 Siponimod (Mayzent, Novartis) is indicated for 'the treatment of adult patients with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price for siponimod is £1,648.23 per pack of 28 tablets, each containing 2 milligrams (excluding VAT; BNF online, May 2020). The company has a commercial arrangement, which would have applied if the technology had been recommended.